Meldex International is a specialty pharmaceutical and healthcare business that uses its XGEL polymer technologies to develop and enhance medicines and healthcare products.
Meldex International develops innovative delivery technology using its XGEL ingestible and non-ingestible polymer platforms to enhance its own pharmaceutical and healthcare products and those of its partners. The Company has product development agreements and strategic alliances with several global pharmaceutical companies including FMC BioPolymer Inc.
Meldex International is an international operation. It has sales and marketing infrastructure in the UK, France, Italy, and the USA; product development in the UK and USA and a product portfolio of branded and generic pharmaceutical and healthcare products in France, Italy, UK, and US.
The Company has approximately 52 employees based at its main locations in:
* London and Cambridge – UK
* Paris – France
* Milan – Italy
* Tampa and Kansas City – USA
Meldex International is a publicly-traded company. The Company is listed on the Alternative Investment Market of the London Stock Exchange.